ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ANIX Anixa Biosciences Inc

3.52
-0.03 (-0.85%)
Last Updated: 13:21:47
Delayed by 15 minutes

Period:

Draw Mode:

Volume 30,367
Bid Price 3.50
Ask Price 3.54
News -
Day High 3.635

Low
2.75

52 Week Range

High
6.45

Day Low 3.48
Company Name Stock Ticker Symbol Market Type
Anixa Biosciences Inc ANIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.03 -0.85% 3.52 13:21:47
Open Price Low Price High Price Close Price Prev Close
3.48 3.48 3.635 3.55
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
186 30,367 $ 3.54 $ 107,392 - 2.75 - 6.45
Last Trade Time Type Quantity Stock Price Currency
13:18:49 25 $ 3.5192 USD

Anixa Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
110.99M 31.71M - 210k -9.81M -0.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Anixa Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ANIX Message Board. Create One! See More Posts on ANIX Message Board See More Message Board Posts

Historical ANIX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.873.9073.393.59106,797-0.35-9.04%
1 Month4.274.703.394.17127,823-0.75-17.56%
3 Months3.765.133.394.16224,655-0.24-6.38%
6 Months3.575.132.753.97132,269-0.05-1.40%
1 Year4.246.452.753.97111,032-0.72-16.98%
3 Years5.168.092.304.53164,594-1.64-31.78%
5 Years4.938.091.333.82187,043-1.41-28.60%

Anixa Biosciences Description

Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer.

Your Recent History

Delayed Upgrade Clock